OrthoPediatrics Corp. (KIDS) News
Filter KIDS News Items
KIDS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KIDS News Highlights
- KIDS's 30 day story count now stands at 4.
- Over the past 23 days, the trend for KIDS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ISRG, RYAN and STAR are the most mentioned tickers in articles about KIDS.
Latest KIDS News From Around the Web
Below are the latest news stories about Orthopediatrics Corp that investors may wish to consider to help them evaluate KIDS as an investment opportunity.
OrthoPediatrics (KIDS) Receives a Buy from NeedhamE ratio of…. |
OrthoPediatrics Announces Preliminary Unaudited Revenue for the Fourth Quarter & Full-Year 2021WARSAW, Ind., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021. Preliminary unaudited fourth quarter 2021 revenue is expected to be $24.8 million, up 31%, when compared to $18.9 million in the fourth quarter of 2020. Preliminary domestic revenue grew 11% |
BTIG Reaffirms Their Buy Rating on OrthoPediatrics (KIDS)In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on OrthoPediatrics (KIDS – Research Report), with a price target of $68.00. The company's shares closed last Tuesday at $57.78. According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 18.4% and a 50.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Organogenesis Holdings, and Zimmer Biomet Holdings. Currently, the analyst consensus on OrthoPediatrics is a Strong Buy with an average price target of $75.75, which is a 33.8% upside from current levels. |
3 Last-Minute Healthcare Stocking StuffersHave a friend or family member on your holiday shopping list who's interested in the stock market? Let's look at three healthcare stocks you can buy this holiday season, hold forever, and feel good about it. Over 55,000 surgeons worldwide have trained on Intuitive Surgical's (NASDAQ: ISRG) minimally-invasive, da Vinci robotic system, which is utilized for a variety of surgical procedures. |
OrthoPediatrics Corp. Continued Double-Diamond Support of International Pediatric Orthopaedic Symposium (IPOS)WARSAW, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support as a Double-Diamond sponsor of the International Pediatric Orthopaedic Symposium (IPOS), which took place December 7 – 11 in Orlando, Florida. Over 400 pediatric orthopedic surgeons attended the meeting. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading education |
OrthoPediatrics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare ConferenceWARSAW, Ind., Nov. 22, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp . (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the release of a fireside chat webcast in connection with the 33 rd Annual Piper Sandler Virtual Healthcare Conference. The fireside chat includes participation by Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer. OrthoPediatrics will be participating in 1x1 investor meetings on December 1, 2021. Meetings can be requested exclusively via Piper Sandler |
OrthoPediatrics Corp. Reports Third Quarter 2021 Financial ResultsThird Quarter 2021 Revenue Increased 13% Year-over-YearWARSAW, Ind., Nov. 03, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the third quarter ended September 30, 2021. Third Quarter 2021 and Business Highlights Generated total revenue of $25.1 million for third quarter 2021, up 13% from $22.2 million in third quarter 2020; |
OrthoPediatrics to Participate in the Stifel 2021 Virtual Healthcare ConferenceWARSAW, Ind., Oct. 26, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Executive Chairman, are scheduled to participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 202 |
OrthoPediatrics Corp. Recognized in COVID Stops Here CampaignWARSAW, Ind., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has been awarded a Silver metal designation as part of the COVID Stops Here campaign for achieving an 80% plus vaccination rate at its Indiana headquarters. |
OrthoPediatrics Expects Q3 Revenue Below Street Estimate; Shares Dip 2.4%Indiana-based bioscience company OrthoPediatrics Corp. (KIDS) expects revenue to increase 13% year-over-year to nearly $25.1 million in the third quarter of 2021, lower than the Street’s estimate of $26.48 million. The projected amount includes the impact of higher respiratory syncytial virus (RSV) cases and COVID-19 Delta cases. Following the announcement, the company’s shares slipped 2.4% in the extended trading session on Thursday after closing nearly 2% down at $57.39. OrthoPediatrics is focused on the design, development, and sale of orthopedic instruments and implants for children. The company continues to expect 2021 revenue in the range of $97 million to $101 million, higher than analysts’ expectations of $96.09 million. |